Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one on rat adipocytes

BACKGROUND: Clinical use of selective PDE3 inhibitors as cardiotonic agents is limited because of their chronotropic and lipolytic side effects. In our previous work, we synthesized a new PDE3 inhibitor named MC2 (6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one) which produced...

Descripción completa

Detalles Bibliográficos
Autores principales: Alinejad, Bagher, Shafiee-Nick, Reza, Sadeghian, Hamid, Ghorbani, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355504/
https://www.ncbi.nlm.nih.gov/pubmed/25880831
http://dx.doi.org/10.1186/s40199-015-0100-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355504/
https://www.ncbi.nlm.nih.gov/pubmed/25880831
http://dx.doi.org/10.1186/s40199-015-0100-2

Ejemplares similares